Mediation analysis of independent treatment effect of guselkumab on health-related quality of life in patients with moderate to severe plaque-type psoriasis: Results from 2 phase 3 studies VOYAGE-1&2

被引：0
|
作者：
Armstrong, April W. [1 ]
Liu, Yan [2 ]
Li, Nan [2 ]
Reich, Kristian [3 ]
Foley, Peter [4 ,5 ]
Li, Shu [6 ]
Fakharzadeh, Steven [2 ,6 ]
Papp, Kim A. [7 ,8 ]
Han, Chenglong [2 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA 90007 USA
[2] Janssen Global Serv LLC, Raritan, NJ USA
[3] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany
[4] Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Vic, Australia
[5] Skin Hlth Inst, Prob Med Res, Carlton, Vic, Australia
[6] Janssen Res & Dev LLC, Raritan, NJ USA
[7] K Papp Clin Res, Waterloo, ON, Canada
[8] Prob Med Res Inc, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27078
引用
收藏
页码：AB128 / AB128
页数：1
相关论文
共 50 条
  • [41] Frequency of gastrointestinal-related serious adverse events among guselkumab-treated patients with moderate to severe psoriasis: A pooled analysis of Voyage 1 and Voyage 2 through 3 years
    Foley, Peter
    Reich, Kristian
    Blauvelt, Andrew
    Bagel, Jerry
    Langley, Richard
    Song, Michael
    Ramachandran, Paraneedharan
    Shen, Yaung-Kaung
    You, Yin
    Lebwohl, Mark
    Griffiths, Christopher E. M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35
  • [42] Impact of guselkumab on fatigue and mediation analysis of independent treatment effect of guselkumab on fatigue in patients with active psoriatic arthritis: Results from DISCOVER-1&2
    Rahman, Proton
    Helliwell, Philip S.
    Deodhar, Atul
    Kollmeier, Alexa P.
    Hsia, Elizabeth
    Zhou, Bei
    Lin, Xiwu
    Han, Chenglong
    Yang, Ya-Wen
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB153 - AB153
  • [43] Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
    Gordon, Kenneth B.
    Sebastian, Michael
    Feldman, Steven R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB24 - AB24
  • [44] Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model
    Papp, Kim A.
    Soliman, Ahmed M.
    Done, Nicolae
    Carley, Christopher
    Lemus Wirtz, Esteban
    Puig, Luis
    DERMATOLOGY AND THERAPY, 2021, 11 (04) : 1291 - 1304
  • [45] Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model
    Kim A. Papp
    Ahmed M. Soliman
    Nicolae Done
    Christopher Carley
    Esteban Lemus Wirtz
    Luis Puig
    Dermatology and Therapy, 2021, 11 : 1291 - 1304
  • [46] Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study
    Revicki, Dennis A.
    Menter, Alan
    Feldman, Steven
    Kimel, Miriam
    Harnam, Neesha
    Willian, Mary K.
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2008, 6 (1)
  • [47] Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study
    Dennis A Revicki
    Alan Menter
    Steven Feldman
    Miriam Kimel
    Neesha Harnam
    Mary K Willian
    Health and Quality of Life Outcomes, 6
  • [48] Sustained improvements in itch, skin pain, and health-related quality of life through 5 years of treatment with ixekizumab in patients with moderate to severe plaque psoriasis
    Gooderham, Melinda
    Elewski, Boni Elizabeth
    Augustin, Matthias
    Iversen, Lars
    Torii, Hideshi
    Burge, Russel
    Zhu, Baojin
    Gallo, Gaia
    Eastman, William
    Foley, Peter
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB19 - AB19
  • [49] Guselkumab therapy improves patient-reported signs, symptoms and health-related quality of life of patients with moderate-severe psoriasis with inadequate response to ustekinumab: Results from phase III NAVIGATE study
    Langley, Richard G.
    Tsai, Tsen-Fang
    Han, Chenglong
    Flavin, Susan
    Song, Michael
    Randazzo, Bruce
    Jiang, Jingzhi
    Li, Shu
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB150 - AB150
  • [50] Ustekinumab improves overall skin response and health-related quality of life in a subset of moderate to severe psoriasis patients with psoriatic arthritis: Analysis of PHOENIX 1 and 2
    Sofen, H.
    Wasel, N.
    Yeilding, N.
    Lee, S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB156 - AB156
12345